Twist Bioscience (NASDAQ:TWST) Insider Dennis Cho Sells 5,000 Shares

Twist Bioscience Corporation (NASDAQ:TWST) insider Dennis Cho sold 5,000 shares of the company’s stock in a transaction on Wednesday, February 11th. The stock was sold at an average price of $49.93, for a total transaction of $249,650.00. Following the transaction, the insider owned 138,581 shares of the company’s stock, valued at approximately $6,919,349.33. The trade was a 3.48% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link.

Dennis Cho also recently made the following trade(s):

• On Tuesday, February 3rd, Dennis Cho sold 1,099 shares of Twist Bioscience stock. The stock was sold at an average price of $46.58, for a total transaction of $51,191.42.
• On Monday, December 22nd, Dennis Cho sold 324 shares of Twist Bioscience stock. The stock was sold at an average price of $34.56, for a total transaction of $11,197.44.

Twist Bioscience Price Performance

Shares of NASDAQ:TWST opened at $49.11 on Friday. Twist Bioscience Corporation has a 52 week low of $23.30 and a 52 week high of $51.00. The company has a 50-day moving average price of $38.63 and a 200 day moving average price of $32.48. The company has a market cap of $3.01 billion, a P/E ratio of -38.37 and a beta of 2.24. The company has a quick ratio of 3.37, a current ratio of 3.78 and a debt-to-equity ratio of 0.03.

Twist Bioscience (NASDAQ:TWST) last issued its earnings results on Monday, February 2nd. The company reported ($0.50) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.02). The business had revenue of $103.70 million for the quarter, compared to analysts’ expectations of $100.32 million. Twist Bioscience had a negative return on equity of 27.16% and a negative net margin of 19.56%.Twist Bioscience’s revenue for the quarter was up 16.9% on a year-over-year basis. Research analysts predict that Twist Bioscience Corporation will post -2.12 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on the stock. Stephens began coverage on shares of Twist Bioscience in a research note on Monday, November 3rd. They set an “overweight” rating and a $41.00 price target on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Twist Bioscience in a report on Monday, December 29th. Robert W. Baird set a $50.00 target price on shares of Twist Bioscience in a report on Tuesday, February 3rd. TD Cowen reissued a “buy” rating on shares of Twist Bioscience in a research note on Thursday, January 8th. Finally, Barclays upped their price target on Twist Bioscience from $39.00 to $50.00 and gave the stock an “overweight” rating in a report on Tuesday, February 3rd. Seven analysts have rated the stock with a Buy rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $45.88.

Institutional Trading of Twist Bioscience

Large investors have recently modified their holdings of the business. Quarry LP purchased a new position in shares of Twist Bioscience during the 3rd quarter worth approximately $28,000. Strategic Advocates LLC grew its holdings in Twist Bioscience by 562.7% during the 4th quarter. Strategic Advocates LLC now owns 1,067 shares of the company’s stock valued at $34,000 after buying an additional 906 shares during the last quarter. Smartleaf Asset Management LLC increased its position in Twist Bioscience by 70.6% during the third quarter. Smartleaf Asset Management LLC now owns 1,068 shares of the company’s stock worth $29,000 after buying an additional 442 shares in the last quarter. SBI Securities Co. Ltd. raised its holdings in shares of Twist Bioscience by 68.9% in the fourth quarter. SBI Securities Co. Ltd. now owns 1,400 shares of the company’s stock worth $44,000 after acquiring an additional 571 shares during the last quarter. Finally, Leonteq Securities AG purchased a new stake in shares of Twist Bioscience in the fourth quarter valued at $48,000.

About Twist Bioscience

Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.

At the core of Twist’s offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.